United States Cancer Angiogenesis Inhibitor Market Report 2016

September 2016 | 120 pages | ID: UB330DFCFEBEN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Cancer Angiogenesis Inhibitor

Revenue, means the sales value of Cancer Angiogenesis Inhibitor

This report studies sales (consumption) of Cancer Angiogenesis Inhibitor in USA market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• Pfizer
• Allergan
• Alnylam Pharmaceuticals
• Amgen
• Angstrom Pharmaceuticals
• Acceleron Pharma
• Biocon
• Bionomics
• CASI Pharmaceuticals
• Celgene Corporation
• Enzon Pharmaceuticals
• Five Prime Therapeutics
• Fujifilm Kyowa Kirin Biologics
• Genentech
• Genexine
• Hetero Drugs
• ImClone Systems
• Intas Pharmaceuticals
• Kyowa Hakko Kirin
• Levolta Pharmaceuticals
• Mabtech
• Marsala Biotech
• Neumedicines
• Novartis
• Oncobiologics
• Onyx Pharmaceuticals

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Type I
• Type II
• Type III

Split by applications, this report focuses on sales, market share and growth rate of Cancer Angiogenesis Inhibitor in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

United States Cancer Angiogenesis Inhibitor Market Report 2016

1 CANCER ANGIOGENESIS INHIBITOR OVERVIEW

1.1 Product Overview and Scope of Cancer Angiogenesis Inhibitor
1.2 Classification of Cancer Angiogenesis Inhibitor
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of Cancer Angiogenesis Inhibitor
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 USA Market Size Sales (Value) and Revenue (Volume) of Cancer Angiogenesis Inhibitor (2011-2021)
  1.4.1 USA Cancer Angiogenesis Inhibitor Sales and Growth Rate (2011-2021)
  1.4.2 USA Cancer Angiogenesis Inhibitor Revenue and Growth Rate (2011-2021)

2 USA CANCER ANGIOGENESIS INHIBITOR COMPETITION BY MANUFACTURERS

2.1 USA Cancer Angiogenesis Inhibitor Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 USA Cancer Angiogenesis Inhibitor Revenue and Share by Manufactures (2015 and 2016)
2.3 USA Cancer Angiogenesis Inhibitor Average Price by Manufactures (2015 and 2016)
2.4 Cancer Angiogenesis Inhibitor Market Competitive Situation and Trends
  2.4.1 Cancer Angiogenesis Inhibitor Market Concentration Rate
  2.4.2 Cancer Angiogenesis Inhibitor Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 USA CANCER ANGIOGENESIS INHIBITOR SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 USA Cancer Angiogenesis Inhibitor Sales and Market Share by Type (2011-2016)
3.2 USA Cancer Angiogenesis Inhibitor Revenue and Market Share by Type (2011-2016)
3.3 USA Cancer Angiogenesis Inhibitor Price by Type (2011-2016)
3.4 USA Cancer Angiogenesis Inhibitor Sales Growth Rate by Type (2011-2016)

4 USA CANCER ANGIOGENESIS INHIBITOR SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 USA Cancer Angiogenesis Inhibitor Sales and Market Share by Application (2011-2016)
4.2 USA Cancer Angiogenesis Inhibitor Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 USA CANCER ANGIOGENESIS INHIBITOR MANUFACTURERS PROFILES/ANALYSIS

5.1 Pfizer
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 Pfizer Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 Allergan
  5.2.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 Allergan Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 Alnylam Pharmaceuticals
  5.3.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 Alnylam Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 Amgen
  5.4.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 Amgen Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 Angstrom Pharmaceuticals
  5.5.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 Angstrom Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 Acceleron Pharma
  5.6.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 Acceleron Pharma Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Biocon
  5.7.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Biocon Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Bionomics
  5.8.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Bionomics Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 CASI Pharmaceuticals
  5.9.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 CASI Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 Celgene Corporation
  5.10.2 Cancer Angiogenesis Inhibitor Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 Celgene Corporation Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview
5.11 Enzon Pharmaceuticals
5.12 Five Prime Therapeutics
5.13 Fujifilm Kyowa Kirin Biologics
5.14 Genentech
5.15 Genexine
5.16 Hetero Drugs
5.17 ImClone Systems
5.18 Intas Pharmaceuticals
5.19 Kyowa Hakko Kirin
5.20 Levolta Pharmaceuticals
5.21 Mabtech
5.22 Marsala Biotech
5.23 Neumedicines
5.24 Novartis
5.25 Oncobiologics
5.26 Onyx Pharmaceuticals

6 CANCER ANGIOGENESIS INHIBITOR MANUFACTURING COST ANALYSIS

6.1 Cancer Angiogenesis Inhibitor Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Cancer Angiogenesis Inhibitor

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Cancer Angiogenesis Inhibitor Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Cancer Angiogenesis Inhibitor Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 USA CANCER ANGIOGENESIS INHIBITOR MARKET FORECAST (2016-2021)

10.1 USA Cancer Angiogenesis Inhibitor Sales, Revenue Forecast (2016-2021)
10.2 USA Cancer Angiogenesis Inhibitor Sales Forecast by Type (2016-2021)
10.3 USA Cancer Angiogenesis Inhibitor Sales Forecast by Application (2016-2021)
10.4 Cancer Angiogenesis Inhibitor Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Author List
Disclosure Section
Research Methodology
Data Source
Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Cancer Angiogenesis Inhibitor
Table Classification of Cancer Angiogenesis Inhibitor
Figure USA Sales Market Share of Cancer Angiogenesis Inhibitor by Type in 2015
Table Application of Cancer Angiogenesis Inhibitor
Figure USA Sales Market Share of Cancer Angiogenesis Inhibitor by Application in 2015
Figure USA Cancer Angiogenesis Inhibitor Sales and Growth Rate (2011-2021)
Figure USA Cancer Angiogenesis Inhibitor Revenue and Growth Rate (2011-2021)
Table USA Cancer Angiogenesis Inhibitor Sales of Key Manufacturers (2015 and 2016)
Table USA Cancer Angiogenesis Inhibitor Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Cancer Angiogenesis Inhibitor Sales Share by Manufacturers
Figure 2016 Cancer Angiogenesis Inhibitor Sales Share by Manufacturers
Table USA Cancer Angiogenesis Inhibitor Revenue by Manufacturers (2015 and 2016)
Table USA Cancer Angiogenesis Inhibitor Revenue Share by Manufacturers (2015 and 2016)
Table 2015 USA Cancer Angiogenesis Inhibitor Revenue Share by Manufacturers
Table 2016 USA Cancer Angiogenesis Inhibitor Revenue Share by Manufacturers
Table USA Market Cancer Angiogenesis Inhibitor Average Price of Key Manufacturers (2015 and 2016)
Figure USA Market Cancer Angiogenesis Inhibitor Average Price of Key Manufacturers in 2015
Figure Cancer Angiogenesis Inhibitor Market Share of Top 3 Manufacturers
Figure Cancer Angiogenesis Inhibitor Market Share of Top 5 Manufacturers
Table USA Cancer Angiogenesis Inhibitor Sales by Type (2011-2016)
Table USA Cancer Angiogenesis Inhibitor Sales Share by Type (2011-2016)
Figure USA Cancer Angiogenesis Inhibitor Sales Market Share by Type in 2015
Table USA Cancer Angiogenesis Inhibitor Revenue and Market Share by Type (2011-2016)
Table USA Cancer Angiogenesis Inhibitor Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Cancer Angiogenesis Inhibitor by Type (2011-2016)
Table USA Cancer Angiogenesis Inhibitor Price by Type (2011-2016)
Figure USA Cancer Angiogenesis Inhibitor Sales Growth Rate by Type (2011-2016)
Table USA Cancer Angiogenesis Inhibitor Sales by Application (2011-2016)
Table USA Cancer Angiogenesis Inhibitor Sales Market Share by Application (2011-2016)
Figure USA Cancer Angiogenesis Inhibitor Sales Market Share by Application in 2015
Table USA Cancer Angiogenesis Inhibitor Sales Growth Rate by Application (2011-2016)
Figure USA Cancer Angiogenesis Inhibitor Sales Growth Rate by Application (2011-2016)
Table Pfizer Basic Information List
Table Pfizer Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Pfizer Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Allergan Basic Information List
Table Allergan Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Allergan Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Alnylam Pharmaceuticals Basic Information List
Table Alnylam Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Alnylam Pharmaceuticals Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Amgen Basic Information List
Table Amgen Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Amgen Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Angstrom Pharmaceuticals Basic Information List
Table Angstrom Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Angstrom Pharmaceuticals Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Acceleron Pharma Basic Information List
Table Acceleron Pharma Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Acceleron Pharma Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Biocon Basic Information List
Table Biocon Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Biocon Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Bionomics Basic Information List
Table Bionomics Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Bionomics Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table CASI Pharmaceuticals Basic Information List
Table CASI Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table CASI Pharmaceuticals Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Celgene Corporation Basic Information List
Table Celgene Corporation Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Celgene Corporation Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Enzon Pharmaceuticals Basic Information List
Table Enzon Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Enzon Pharmaceuticals Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Five Prime Therapeutics Basic Information List
Table Five Prime Therapeutics Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Five Prime Therapeutics Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Fujifilm Kyowa Kirin Biologics Basic Information List
Table Fujifilm Kyowa Kirin Biologics Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Fujifilm Kyowa Kirin Biologics Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Genentech Basic Information List
Table Genentech Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Genentech Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Genexine Basic Information List
Table Genexine Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Genexine Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Hetero Drugs Basic Information List
Table Hetero Drugs Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Hetero Drugs Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table ImClone Systems Basic Information List
Table ImClone Systems Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table ImClone Systems Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Intas Pharmaceuticals Basic Information List
Table Intas Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Intas Pharmaceuticals Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Kyowa Hakko Kirin Basic Information List
Table Kyowa Hakko Kirin Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Kyowa Hakko Kirin Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Levolta Pharmaceuticals Basic Information List
Table Levolta Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Levolta Pharmaceuticals Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Mabtech Basic Information List
Table Mabtech Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Mabtech Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Marsala Biotech Basic Information List
Table Marsala Biotech Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Marsala Biotech Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Neumedicines Basic Information List
Table Neumedicines Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Neumedicines Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Novartis Basic Information List
Table Novartis Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Novartis Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Oncobiologics Basic Information List
Table Oncobiologics Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Oncobiologics Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Onyx Pharmaceuticals Basic Information List
Table Onyx Pharmaceuticals Cancer Angiogenesis Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Onyx Pharmaceuticals Cancer Angiogenesis Inhibitor Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Cancer Angiogenesis Inhibitor
Figure Manufacturing Process Analysis of Cancer Angiogenesis Inhibitor
Figure Cancer Angiogenesis Inhibitor Industrial Chain Analysis
Table Raw Materials Sources of Cancer Angiogenesis Inhibitor Major Manufacturers in 2015
Table Major Buyers of Cancer Angiogenesis Inhibitor
Table Distributors/Traders List
Figure USA Cancer Angiogenesis Inhibitor Production and Growth Rate Forecast (2016-2021)
Figure USA Cancer Angiogenesis Inhibitor Revenue and Growth Rate Forecast (2016-2021)
Table USA Cancer Angiogenesis Inhibitor Production Forecast by Type (2016-2021)
Table USA Cancer Angiogenesis Inhibitor Consumption Forecast by Application (2016-2021)